AG
MYGN icon

Algert Global’s Myriad Genetics MYGN Stock Holding History

Algert Global’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-363,822
Closed -$1.64M – 1356
2026
Q1 		$1.64M Sell
363,822
-1,635
-0.4% -$8.52K 0.02% 756
2025
Q4 		$2.25M Sell
365,457
-547,608
-60% -$3.97M 0.04% 682
2025
Q3 		$6.6M Buy
+913,065
New +$5.42M 0.11% 321
2025
Q2 		– Sell
-180,548
Closed -$1.6M – 1287
2025
Q1 		$1.6M Buy
180,548
+120,450
+200% +$1.45M 0.04% 667
2024
Q4 		$824K Buy
60,098
+38,818
+182% +$716K 0.02% 823
2024
Q3 		$583K Buy
21,280
+12,232
+135% +$331K 0.02% 871
2024
Q2 		$221K Buy
+9,048
New +$199K 0.01% 1246
2014
Q2 		– Sell
-9,950
Closed -$340K – 330
2014
Q1 		$340K Sell
9,950
-4,200
-30% -$130K 0.13% 222
2013
Q4 		$297K Buy
+14,150
New +$358K 0.08% 286

Other funds holding MYGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Algert Global's MYGN Position: Q2 2026 in Review

Algert Global sold out of Myriad Genetics (MYGN) in Q2 2026, closing a stake of 363,822 shares — an estimated $1.64M sold.

Algert Global first reported a position in MYGN in Q4 2013 and held it in 9 quarters. The position peaked at $6.6M in Q3 2025. 197 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

  • Algert Global reported no remaining Myriad Genetics position as of Q2 2026 after selling out during the quarter.
  • Algert Global sold 363,822 Myriad Genetics shares in Q2 2026, an estimated $1.64M.
  • Algert Global first reported a position in Myriad Genetics in Q4 2013 and held it in 9 quarters.
  • Algert Global's Myriad Genetics position peaked at $6.6M in Q3 2025.
  • 197 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on Algert Global's 13F filing for Q2 2026, filed 13 Aug 2026.